Ocarina Networks said this week that Cornell University's Center for Advanced Computing is testing its system for compressing large amounts of life-science data, including data from second-generation sequencers.
Based on their assessment of SNP data for several complex diseases, researchers from the University of Pittsburgh and the University of California at Los Angeles warn that genetic tests based on existing GWAS may not be refined enough to accurately predict individual disease risk.
It was not immediately clear whether PerkinElmer would divest all of its proteomics assets or retain a portion of them, though it described them as “discontinued operations” during its fourth-quarter earnings statement.
Funding from the National Institutes of Health for all proteomics-related research shrank by almost 3 percent in fiscal 2008, according to an analysis of NIH data by GWDN sister publication ProteoMonitor.
Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.
Details of the deal are sparse, but the partners said they hope their research will lead to the development of genetic tests that can gauge patients’ predisposition to rare diseases and help target individuals most likely to respond to drugs made by MondoBiotech.
Researchers from the Netherlands have uncovered a new gene expression signature linked to ovarian cancer survival that is providing hints about potential pathways of importance for the disease. But authors warn that using such signatures for guiding treatment may be a ways off.